1975-2020年预防、筛查和治疗措施避免癌症死亡的估算
该模型研究基于美国人群水平癌症死亡率数据,量化1975至2020年间预防、筛查和治疗对乳腺癌、宫颈癌、结直肠癌、肺癌和前列腺癌累计避免死亡数的贡献。
要点
- 肺癌死亡主要因吸烟减少而避免(98%),筛查贡献低且2014年前治疗多为姑息性。
- 筛查对乳腺癌避免死亡的贡献为25%,对前列腺癌为56%,宫颈癌几乎完全归因于筛查。
核心结论
- 过去45年间,预防和筛查避免了上述五种癌症的大多数死亡,但各癌种贡献不同。
- 减少美国癌症负担需增加有效干预措施的推广及新技术和新发现。
研究设计与样本
- 基于人群水平癌症死亡率数据的模型研究,扩展癌症干预与监测建模网络已发表模型的输出至2020年。
- 模型输入基于危险因素、癌症发病、癌症生存和其他原因死亡的国家数据,以及预防、筛查和治疗的推广与效果。
- 使用源自美国人群多个出生队列参数模拟或建模的数据。
主要发现
- 筛查对乳腺癌避免死亡的贡献为25%。
- 宫颈癌避免死亡几乎完全通过筛查和癌前病变切除实现,研究期间治疗进展有限。
- 结直肠癌避免死亡中79%归因于筛查和癌前息肉切除或早期检测,21%归因于治疗进展。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cancer mortality has decreased over time, but the contributions of different interventions across the cancer control continuum to averting cancer deaths have not been systematically evaluated across major cancer sites. OBJECTIVE: To quantify the contributions of prevention, screening (to remove precursors [interception] or early detection), and treatment to cumulative number of cancer deaths averted from 1975 to 2020 for breast, cervical, colorectal, lung, and prostate cancers. DESIGN, SETTING, AND PARTICIPANTS: In this model-based study using population-level cancer mortality data, outputs from published models developed by the Cancer Intervention and Surveillance Modeling Network were extended to quantify cancer deaths averted through 2020. Model inputs were based on national data on risk factors, cancer incidence, cancer survival, and mortality due to other causes, and dissemination and effects of prevention, screening (for interception and early detection), and treatment. Simulated or modeled data using parameters derived from multiple birth cohorts of the US population were used. INTERVENTIONS: Primary prevention via smoking reduction (lung), screening for interception (cervix and colorectal) or early detection (breast, cervix, colorectal, and prostate), and therapy (breast, colorectal, lung, and prostate). MAIN OUTCOMES AND MEASURES: The estimated cumulative number of cancer deaths averted with interventions vs no advances. RESULTS: An estimated 5.94 million cancer deaths were averted for breast, cervical, colorectal, lung, and prostate cancers combined. Cancer prevention and screening efforts averted 8 of 10 of these deaths (4.75 million averted deaths). The contribution of each intervention varied by cancer site. Screening accounted for 25% of breast cancer deaths averted. Averted cervical cancer deaths were nearly completely averted through screening and removal of cancer precursors as treatment advances were modest during the study period. Averted colorectal cancer deaths were averted because of screening and removal of precancerous polyps or early detection in 79% and treatment advances in 21%. Most lung cancer deaths were avoided by smoking reduction (98%) because screening uptake was low and treatment largely palliative before 2014. Screening contributed to 56% of averted prostate cancer deaths. CONCLUSIONS AND RELEVANCE: Over the past 45 years, cancer prevention and screening accounted for most cancer deaths averted for these causes; however, their contribution varied by cancer site according to these models using population-level cancer mortality data. Despite progress, efforts to reduce the US cancer burden will require increased dissemination of effective interventions and new technologies and discoveries.
引用
- Goddard KAB, Feuer EJ, Mandelblatt JS, et al. Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020. JAMA Oncol. 2025. PMID: 39636625. doi:10.1001/jamaoncol.2024.5381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。